Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5690750 | Gynecologic Oncology | 2016 | 5 Pages |
Abstract
CD47 is expressed at high frequency in EOC. Patients with CD47lo EOC had a better treatment response to standard therapy, and trended towards improved OS. This demonstrates that while CD47 may be an immunologic shield that may be considered for targeted therapies, it is likely that it operates in concert with other mechanisms of immune evasion. Future studies to evaluate CD47 expression with other known mechanisms of immune escape in the tumor microenvironment may help further define its role.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
R.M. Brightwell, K.S. Grzankowski, S. Lele, K. Eng, M. Arshad, H. Chen, K. Odunsi,